Open AccessRegulation of tumor infiltrated innate immune cells by adenosine
Author(s) -
Regina Strakhova,
Octavia Cadassou,
Emeline CrosPerrial,
Lars Petter Jordheim
Publication year - 2020
Publication title -
purinergic signalling
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.064
H-Index - 59
eISSN - 1573-9546
pISSN - 1573-9538
DOI - 10.1007/s11302-020-09701-6
Subject(s) - adenosine , immune system , innate immune system , acquired immune system , biology , purinergic signalling , microbiology and biotechnology , cancer cell , adenosine receptor , effector , innate lymphoid cell , immunology , receptor , cancer , biochemistry , agonist , genetics
Cancer has the ability to escape the immune system using different molecular actors. Adenosine is known to be involved in mechanisms which control inflammatory reactions and prevent excessive immune response. This purine nucleoside can be translocated from the cell or produced in the extracellular space by 5'-ectonucleotidases. Once bound to its receptors on the surface of immune effector cells, adenosine activates various molecular pathways, which lead to functional inhibition of the cell or its death. Some tumors are infiltrated by the different cells of immune system but are able to use adenosine as an immunosuppressive molecule and thus inhibit immune anticancer response. This mechanism is well described on adaptive cells, but much less on innate cells. This review outlines major effects of adenosine on innate immune cells, its consequences on cancer progression, and possible ways to block the adenosine-dependent immunosuppressive effect.